针对量子粒子群算法在处理自变量具有有限定义域的问题时易陷入局部最优解的问题,对算法的量子模型加以改进,提出了基于非对称势的量子粒子群算法(asymmetric potential well based quantum particle swarm optimization,AQPSO)。该算...针对量子粒子群算法在处理自变量具有有限定义域的问题时易陷入局部最优解的问题,对算法的量子模型加以改进,提出了基于非对称势的量子粒子群算法(asymmetric potential well based quantum particle swarm optimization,AQPSO)。该算法认为粒子处于非对称势阱中,势阱的参数由当前的最优位置和自变量的定义域共同决定。而在求解粒子在空间分布的波函数时,又采用了参数消减方法,只需人工指定越限概率,简化算法流程。最后,通过算例验证,该方法的全局搜索能力显著提升,在处理高维、复杂、强干扰性问题时,具有显著优势。展开更多
AIM: Tacrolimus shows considerable interindividual pharmacokinetic variability, therapeutic drug monitoring of trough blood concentration is necessary to avoid adverse effects. CYP3A5 and P-glycoprotein (P-gp, encoded...AIM: Tacrolimus shows considerable interindividual pharmacokinetic variability, therapeutic drug monitoring of trough blood concentration is necessary to avoid adverse effects. CYP3A5 and P-glycoprotein (P-gp, encoded by MDR1) are involved in tacrolimus’ metabolism and absorption process. This study is to investigate whether tacrolimus dosage adjustment is affected by the polymorphism in CYP3A5 and MDR1 in Chinese liver transplant patients. METHODS: Forty-nine liver transplant patients treated with tacrolimus were enrolled in this study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis was applied to determine the genotype of CYP3A5 and MDR1. Tacrolimus blood tough concentration was measured by FPIA, and concentration/dose ratio(C/D) was investigated at day 7, day 14 and 1 month after liver transplantation. RESULTS: The CD ratios in recipient with CYP3A5*1/*1 (*1/*3) were significantly lower than those of CYP3A5*3/*3 patients after liver transplantation, and the C/D ratios of CYP3A5*1/*1 ,*1/*3 and *3/*3 were shown as follows: 76, 82±18, 164±51 at 7 days; 32, 76±19, 132±31 at 14 days; 36, 65±25, 122±32 at 1 month. No significant difference was found among the MDR1 G2677T/A and C3435T genotype. CONCLUSION: There was no relationship between MDR1 gene polymorphism (C3435T, G2677T/A) and tacrolimus C/D ratio in Chinese liver transplantation patients. CYP3A5 *3 polymorphism is correlated with the whole blood concentration of tacrolimus and dose requirement. The intestinal CYP3A5 plays an important role in the metabolism of orally administered tacrolimus in the first month after liver transplantation.展开更多
文摘针对量子粒子群算法在处理自变量具有有限定义域的问题时易陷入局部最优解的问题,对算法的量子模型加以改进,提出了基于非对称势的量子粒子群算法(asymmetric potential well based quantum particle swarm optimization,AQPSO)。该算法认为粒子处于非对称势阱中,势阱的参数由当前的最优位置和自变量的定义域共同决定。而在求解粒子在空间分布的波函数时,又采用了参数消减方法,只需人工指定越限概率,简化算法流程。最后,通过算例验证,该方法的全局搜索能力显著提升,在处理高维、复杂、强干扰性问题时,具有显著优势。
基金This work was supported by the National Natural Science Foundation of China （ No. 30500626 ）.
文摘AIM: Tacrolimus shows considerable interindividual pharmacokinetic variability, therapeutic drug monitoring of trough blood concentration is necessary to avoid adverse effects. CYP3A5 and P-glycoprotein (P-gp, encoded by MDR1) are involved in tacrolimus’ metabolism and absorption process. This study is to investigate whether tacrolimus dosage adjustment is affected by the polymorphism in CYP3A5 and MDR1 in Chinese liver transplant patients. METHODS: Forty-nine liver transplant patients treated with tacrolimus were enrolled in this study. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis was applied to determine the genotype of CYP3A5 and MDR1. Tacrolimus blood tough concentration was measured by FPIA, and concentration/dose ratio(C/D) was investigated at day 7, day 14 and 1 month after liver transplantation. RESULTS: The CD ratios in recipient with CYP3A5*1/*1 (*1/*3) were significantly lower than those of CYP3A5*3/*3 patients after liver transplantation, and the C/D ratios of CYP3A5*1/*1 ,*1/*3 and *3/*3 were shown as follows: 76, 82±18, 164±51 at 7 days; 32, 76±19, 132±31 at 14 days; 36, 65±25, 122±32 at 1 month. No significant difference was found among the MDR1 G2677T/A and C3435T genotype. CONCLUSION: There was no relationship between MDR1 gene polymorphism (C3435T, G2677T/A) and tacrolimus C/D ratio in Chinese liver transplantation patients. CYP3A5 *3 polymorphism is correlated with the whole blood concentration of tacrolimus and dose requirement. The intestinal CYP3A5 plays an important role in the metabolism of orally administered tacrolimus in the first month after liver transplantation.
